Company Overview - Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, focused on effecting mergers, share exchanges, asset acquisitions, and similar business combinations with various businesses or entities [3] - The company has not yet selected a business combination target and has not initiated substantive discussions with any potential targets [3] - Aimfinity will not complete its initial business combination with any target headquartered in China or conducting a majority of its business in China [3] Business Combination Update - The company announced an extension of the deadline to complete its initial business combination from February 28, 2025, to March 28, 2025, with a Monthly Extension Payment of $55,823.8, equating to $0.05 per Class A ordinary share held by public shareholders [1][2] - This extension is the second of nine monthly extensions allowed under the company's current charter, which permits monthly extensions from January 28, 2025, until October 28, 2025 [2] Merger Agreement - On October 13, 2023, Aimfinity entered into a Merger Agreement with Docter Inc., proposing a business combination involving a reincorporation merger and an acquisition merger [4] - The press release indicates that further information regarding the proposed business combination will be provided in a proxy statement/prospectus to be mailed to stockholders [4]

Core Insights - Senseonics Holdings, Inc. received FDA approval for the Eversense 365 Continuous Glucose Monitoring (CGM) system and launched it in partnership with Ascensia Diabetes Care, marking a significant advancement in diabetes care [1][3] - The patient base for Eversense increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients [1][6] - The company reported total revenue of $8.3 million for Q4 2024, a slight increase from $8.0 million in Q4 2023, with U.S. revenue remaining stable at $6.2 million [4] Financial Performance - Fourth quarter 2024 gross profit was $4.0 million, up from $1.1 million in Q4 2023, primarily due to improved margins on the Eversense 365 product [5] - For the full year 2024, total revenue was $22.5 million, slightly up from $22.4 million in 2023, with U.S. revenue increasing to $15.3 million from $14.1 million [9] - The net loss for Q4 2024 was $15.5 million, a reduction from a net loss of $17.2 million in Q4 2023, attributed to improved gross profit margins [8] Operational Highlights - The Eversense 365 system was launched in the U.S. in 2024, and early performance indicators showed positive results, including record new patient shipments of approximately 600 in December [6] - The company exceeded 2,400 annual U.S. prescribers for Eversense in 2024, with 81% of patients switching from competitive CGMs [6] - Senseonics initiated a collaboration with Mercy Health to study the use of Eversense and remote patient monitoring [6] Future Outlook - For 2025, Senseonics expects global net revenue to be approximately $34-38 million, anticipating a doubling of the global patient base [15] - The company plans to enhance gross margins throughout 2025, projecting margins between 25-30% for the year [15] - Cash utilization in 2025 is expected to be between $50-$60 million as the company continues to roll out Eversense 365 [15]

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 3845 26-4333375 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on September 22, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 142 West 57 Street, 11Floor New York, New York 10019 Telephone: (646) 828-8258 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 3829 82-1512711 (State or other jurisdiction of (Primary Standard Industrial (I ...

As filed with the Securities and Exchange Commission on July 27, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) 142 West 57 Street, 11Floor New York, New York 10019 Telephone: (646) 828-8258 (Address, including zip code, and telephone number, including area code, of registrant's prin ...